A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial of TG103 Injection Monotherapy Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 25 Aug 2025
At a glance
- Drugs GX G6 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Most Recent Events
- 08 Aug 2025 Status changed from not yet recruiting to active, no longer recruiting.
- 19 Feb 2024 New trial record